New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature
Ustekinumab was responsible for three cases of de novo vitiligo and secukinumab for only one case. [...]new-onset vitiligo could be triggered due to blockade of the TNFa/IL-23/IL-17 pathway. High serum TNFa [6, 7] concentrations and elevated circulation interleukin-17 (IL-17) levels [8] were found i...
Gespeichert in:
| Veröffentlicht in: | Clinical drug investigation 2020-11, Vol.40 (11), p.1089-1091 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1091 |
|---|---|
| container_issue | 11 |
| container_start_page | 1089 |
| container_title | Clinical drug investigation |
| container_volume | 40 |
| creator | Nieto-Benito, Lula María Baniandrés-Rodríguez, Ofelia |
| description | Ustekinumab was responsible for three cases of de novo vitiligo and secukinumab for only one case. [...]new-onset vitiligo could be triggered due to blockade of the TNFa/IL-23/IL-17 pathway. High serum TNFa [6, 7] concentrations and elevated circulation interleukin-17 (IL-17) levels [8] were found in patients with vitiligo, which explains the reasons for the use of anti-TNFa agents and IL-17 inhibitors to treat this condition [9], but no clinical response was obtained. [...]we describe two new cases of de novo vitiligo (of only three cases published in the literature) during anti-IL17 treatment in two psoriatic patients during secukinumab treatment. |
| doi_str_mv | 10.1007/s40261-020-00964-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2438992151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2438992151</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-d1d8fe9090d621d9c076e1fa9e91ccc8b4e04827e0b271818b134a7581e830a93</originalsourceid><addsrcrecordid>eNp9kU1P3DAQhq2qVflo_0APyFIvvRhm7Gxi94a25UNaFYlue7WcZAKGTbK1HSL-PVkWqMSB04xGz7wzel_GviAcIkBxFDOQOQqQIABMnonxHdtFLIxAg_r9Y6-EnOVqh-3FeAOAOebyI9tRUudSKbXLml80iosuUuJ_ffIrf9XzH0Pw3RVfBnKppS7x0adr_puq4dZ3Q-vK7_yS1n1IvG_4cuz53EWK3HX1NL_zNG7m6Zr4wicKLg2BPrEPjVtF-vxU99mfk5_L-ZlYXJyez48XolLFLIkaa92QAQN1LrE2FRQ5YeMMGayqSpcZQaZlQVDKAjXqElXmiplG0gqcUfvs21Z3Hfp_A8VkWx8rWq1cR_0QrcyUNkbiDCf06yv0ph9CN303UdqAggyziZJbqgp9jIEauw6-deHeIthNCnabgp1SsI8p2HFaOniSHsqW6peVZ9snQG2BuN5YTeH_7TdkHwCXNpHa</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489030414</pqid></control><display><type>article</type><title>New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature</title><source>SpringerLink Journals - AutoHoldings</source><creator>Nieto-Benito, Lula María ; Baniandrés-Rodríguez, Ofelia</creator><creatorcontrib>Nieto-Benito, Lula María ; Baniandrés-Rodríguez, Ofelia</creatorcontrib><description>Ustekinumab was responsible for three cases of de novo vitiligo and secukinumab for only one case. [...]new-onset vitiligo could be triggered due to blockade of the TNFa/IL-23/IL-17 pathway. High serum TNFa [6, 7] concentrations and elevated circulation interleukin-17 (IL-17) levels [8] were found in patients with vitiligo, which explains the reasons for the use of anti-TNFa agents and IL-17 inhibitors to treat this condition [9], but no clinical response was obtained. [...]we describe two new cases of de novo vitiligo (of only three cases published in the literature) during anti-IL17 treatment in two psoriatic patients during secukinumab treatment.</description><identifier>ISSN: 1173-2563</identifier><identifier>EISSN: 1179-1918</identifier><identifier>DOI: 10.1007/s40261-020-00964-w</identifier><identifier>PMID: 32862333</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Autoimmune diseases ; Biological products ; Chronic illnesses ; Cytokines ; Drug dosages ; Inflammatory diseases ; Internal Medicine ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Patients ; Pharmacology/Toxicology ; Pharmacotherapy ; Psoriasis ; Research Letter ; Thyroid gland ; Tumor necrosis factor-TNF ; Vitiligo</subject><ispartof>Clinical drug investigation, 2020-11, Vol.40 (11), p.1089-1091</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Copyright Springer Nature B.V. Nov 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-d1d8fe9090d621d9c076e1fa9e91ccc8b4e04827e0b271818b134a7581e830a93</citedby><cites>FETCH-LOGICAL-c375t-d1d8fe9090d621d9c076e1fa9e91ccc8b4e04827e0b271818b134a7581e830a93</cites><orcidid>0000-0002-7609-2736</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40261-020-00964-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40261-020-00964-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32862333$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nieto-Benito, Lula María</creatorcontrib><creatorcontrib>Baniandrés-Rodríguez, Ofelia</creatorcontrib><title>New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature</title><title>Clinical drug investigation</title><addtitle>Clin Drug Investig</addtitle><addtitle>Clin Drug Investig</addtitle><description>Ustekinumab was responsible for three cases of de novo vitiligo and secukinumab for only one case. [...]new-onset vitiligo could be triggered due to blockade of the TNFa/IL-23/IL-17 pathway. High serum TNFa [6, 7] concentrations and elevated circulation interleukin-17 (IL-17) levels [8] were found in patients with vitiligo, which explains the reasons for the use of anti-TNFa agents and IL-17 inhibitors to treat this condition [9], but no clinical response was obtained. [...]we describe two new cases of de novo vitiligo (of only three cases published in the literature) during anti-IL17 treatment in two psoriatic patients during secukinumab treatment.</description><subject>Autoimmune diseases</subject><subject>Biological products</subject><subject>Chronic illnesses</subject><subject>Cytokines</subject><subject>Drug dosages</subject><subject>Inflammatory diseases</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Psoriasis</subject><subject>Research Letter</subject><subject>Thyroid gland</subject><subject>Tumor necrosis factor-TNF</subject><subject>Vitiligo</subject><issn>1173-2563</issn><issn>1179-1918</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1P3DAQhq2qVflo_0APyFIvvRhm7Gxi94a25UNaFYlue7WcZAKGTbK1HSL-PVkWqMSB04xGz7wzel_GviAcIkBxFDOQOQqQIABMnonxHdtFLIxAg_r9Y6-EnOVqh-3FeAOAOebyI9tRUudSKbXLml80iosuUuJ_ffIrf9XzH0Pw3RVfBnKppS7x0adr_puq4dZ3Q-vK7_yS1n1IvG_4cuz53EWK3HX1NL_zNG7m6Zr4wicKLg2BPrEPjVtF-vxU99mfk5_L-ZlYXJyez48XolLFLIkaa92QAQN1LrE2FRQ5YeMMGayqSpcZQaZlQVDKAjXqElXmiplG0gqcUfvs21Z3Hfp_A8VkWx8rWq1cR_0QrcyUNkbiDCf06yv0ph9CN303UdqAggyziZJbqgp9jIEauw6-deHeIthNCnabgp1SsI8p2HFaOniSHsqW6peVZ9snQG2BuN5YTeH_7TdkHwCXNpHa</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Nieto-Benito, Lula María</creator><creator>Baniandrés-Rodríguez, Ofelia</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7609-2736</orcidid></search><sort><creationdate>20201101</creationdate><title>New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature</title><author>Nieto-Benito, Lula María ; Baniandrés-Rodríguez, Ofelia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-d1d8fe9090d621d9c076e1fa9e91ccc8b4e04827e0b271818b134a7581e830a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Autoimmune diseases</topic><topic>Biological products</topic><topic>Chronic illnesses</topic><topic>Cytokines</topic><topic>Drug dosages</topic><topic>Inflammatory diseases</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Psoriasis</topic><topic>Research Letter</topic><topic>Thyroid gland</topic><topic>Tumor necrosis factor-TNF</topic><topic>Vitiligo</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nieto-Benito, Lula María</creatorcontrib><creatorcontrib>Baniandrés-Rodríguez, Ofelia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical drug investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nieto-Benito, Lula María</au><au>Baniandrés-Rodríguez, Ofelia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature</atitle><jtitle>Clinical drug investigation</jtitle><stitle>Clin Drug Investig</stitle><addtitle>Clin Drug Investig</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>40</volume><issue>11</issue><spage>1089</spage><epage>1091</epage><pages>1089-1091</pages><issn>1173-2563</issn><eissn>1179-1918</eissn><abstract>Ustekinumab was responsible for three cases of de novo vitiligo and secukinumab for only one case. [...]new-onset vitiligo could be triggered due to blockade of the TNFa/IL-23/IL-17 pathway. High serum TNFa [6, 7] concentrations and elevated circulation interleukin-17 (IL-17) levels [8] were found in patients with vitiligo, which explains the reasons for the use of anti-TNFa agents and IL-17 inhibitors to treat this condition [9], but no clinical response was obtained. [...]we describe two new cases of de novo vitiligo (of only three cases published in the literature) during anti-IL17 treatment in two psoriatic patients during secukinumab treatment.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32862333</pmid><doi>10.1007/s40261-020-00964-w</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-7609-2736</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1173-2563 |
| ispartof | Clinical drug investigation, 2020-11, Vol.40 (11), p.1089-1091 |
| issn | 1173-2563 1179-1918 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2438992151 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Autoimmune diseases Biological products Chronic illnesses Cytokines Drug dosages Inflammatory diseases Internal Medicine Medicine Medicine & Public Health Monoclonal antibodies Patients Pharmacology/Toxicology Pharmacotherapy Psoriasis Research Letter Thyroid gland Tumor necrosis factor-TNF Vitiligo |
| title | New-Onset Vitiligo During Treatment with Secukinumab: Report of Two Cases and Review of the Literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T19%3A59%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New-Onset%20Vitiligo%20During%20Treatment%20with%20Secukinumab:%20Report%20of%20Two%20Cases%20and%20Review%20of%20the%20Literature&rft.jtitle=Clinical%20drug%20investigation&rft.au=Nieto-Benito,%20Lula%20Mar%C3%ADa&rft.date=2020-11-01&rft.volume=40&rft.issue=11&rft.spage=1089&rft.epage=1091&rft.pages=1089-1091&rft.issn=1173-2563&rft.eissn=1179-1918&rft_id=info:doi/10.1007/s40261-020-00964-w&rft_dat=%3Cproquest_cross%3E2438992151%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2489030414&rft_id=info:pmid/32862333&rfr_iscdi=true |